EPRX
Eupraxia PharmaceuticalsEPRX
EPRX
About: Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
Employees: 33
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
26% more capital invested
Capital invested by funds: $5.63M [Q4 2024] → $7.09M (+$1.45M) [Q1 2025]
22% more funds holding
Funds holding: 9 [Q4 2024] → 11 (+2) [Q1 2025]
0.92% more ownership
Funds ownership: 5.13% [Q4 2024] → 6.05% (+0.92%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for EPRX.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 2, 2025. Pursuant to a resolution passed by ballot vote, all of the six nominees proposed by management for election to the Company's board of directors (the “Board”) at the Meeting and listed in the Company's Management Information Circular dated April 25, 2025, were elected.
Neutral
GlobeNewsWire
1 month ago
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE)
Neutral
GlobeNewsWire
1 month ago
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE)
Neutral
GlobeNewsWire
1 month ago
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May
VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company's management and scientific teams will present at the following investor and scientific conferences in April and May: Osteoarthritis Research Society International World Congress April 24-27, 2025 Dr. Phil Conaghan, a member of the Company's OA Clinical Advisory Board, will be presenting a poster on the Company's behalf at the Osteoarthritis Research Society International (“OARSI”) World Congress 2025, being held April 24-27, 2025 in Incheon (Seoul), South Korea. Poster Details Poster Title: EP-104IAR (extended-release intra-articular injection of fluticasone propionate) shows sustained pain response for subjects with moderate baseline pain and BMI less than 30 in SPRINGBOARD, a Phase 2, randomized, 24-week study of osteoarthritis of the knee.
Neutral
PRNewsWire
2 months ago
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
VICTORIA, BC , March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise.
Neutral
PRNewsWire
3 months ago
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Histological scores and symptom scores continue to improve as EP-104GI dose, and area of esophageal coverage, increase Cohort 6 showed the greatest symptom relief scores ("SDI") of all cohorts to date at 12 weeks Cohort 6 had the greatest magnitude and percentage change in tissue health scores ("EoEHSS") of any cohort to date at 12 weeks Cohort 6 saw the greatest reduction in Peak Eosinophil Count ("PEC") of any cohort to date Cohort 5 demonstrated the greatest symptom score reduction (SDI) seen to date at 24 weeks, showing continuously improving symptom relief over that time For tissue health (EoEHSS) and PEC there is a clear dose-response from Cohorts 3 to 6, with Cohort 6 showing the greatest response No serious adverse events nor any events of oral or gastrointestinal candidiasis were reported in any of the six cohorts Cohort 7 is fully enrolled, with 12-week data expected in Q2 2025 Company to host Webinar to discuss data from RESOLVE trial on Wednesday, February 26 th at 11:00am PT (Link to Webinar) VICTORIA, BC , Feb. 25, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company specializing in precision local drug delivery, today announced additional positive clinical data from its ongoing RESOLVE Phase 1b/2a trial evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE"). EoE is an inflammatory-mediated disease in which white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food.
Neutral
PRNewsWire
3 months ago
Eupraxia Pharmaceuticals Announces CFO Succession
- Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC , Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities.
Neutral
PRNewsWire
6 months ago
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
DiffuSphere™ is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues, enhancing efficacy while minimizing systemic drug levels to optimize safety In clinical trials, a single administration of DiffuSphere™ successfully delivered fluticasone propionate for at least six months in patients with eosinophilic esophagitis or osteoarthritis DiffuSphere™ has shown its versatility with various drug classes, supporting the possibility to treat multiple types of pain, infectious diseases, eye diseases and cancers VICTORIA, BC , Nov. 20, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today unveiled new pharmacokinetic ("PK") data from its Phase 2a Eosinophilic Esophagitis ("EoE") program. Management believes these data underscore the unique capabilities of Eupraxia's proprietary DiffuSphere™ platform technology, which aims to provide precise, localized, safe, and effective long-lasting drug delivery.
Neutral
PRNewsWire
6 months ago
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
VICTORIA, BC , Nov. 14, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company will be presenting a poster at the American College of Rheumatology (the "ACR") Convergence 2024 Annual Meeting, being held in Washington, D.C. from November 14-19, 2024.
Neutral
PRNewsWire
7 months ago
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalence Registration for the webinar now open to the public by visiting EPRXNOV1524.TribePublic.com VICTORIA, BC , Nov. 13, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that Eupraxia's CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar Presentation and Q&A Event titled, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed".
Charts implemented using Lightweight Charts™